{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:03:41Z","timestamp":1792839821865,"version":"4.5.0"},"reference-count":93,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["NMRC\/CIRG\/1351\/2013"],"award-info":[{"award-number":["NMRC\/CIRG\/1351\/2013"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["NMRC\/CIRG\/1479\/2017"],"award-info":[{"award-number":["NMRC\/CIRG\/1479\/2017"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["NMRC\/CSA-SI\/0016\/2017"],"award-info":[{"award-number":["NMRC\/CSA-SI\/0016\/2017"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.jhep.2022.12.017","type":"journal-article","created":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T02:09:04Z","timestamp":1672193344000},"page":"731-741","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["A critique and systematic review of the clinical utility of hepatitis B core-related antigen"],"prefix":"10.1016","volume":"78","author":[{"given":"Celina","family":"Adraneda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8743-997X","authenticated-orcid":false,"given":"Yong Chuan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8293-8187","authenticated-orcid":false,"given":"Ee Jin","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guan Sen","family":"Kew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atefeh","family":"Khakpoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0994-4932","authenticated-orcid":false,"given":"Seng Gee","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2022.12.017_bib1","series-title":"Global hepatitis report 2017","author":"World Health Organization","year":"2017"},{"key":"10.1016\/j.jhep.2022.12.017_bib2","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.12.017_bib3","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.12.017_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2022.12.017_bib5","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1002\/hep.22929","article-title":"Clinical outcomes in adults with chronic hepatitis B in association with patient and viral characteristics: a systematic review of evidence","volume":"49","author":"Taylor","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.12.017_bib6","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jhep.2022.12.017_bib7","doi-asserted-by":"crossref","first-page":"47","DOI":"10.18773\/austprescr.2009.023","article-title":"Surrogate outcome markers in research and clinical practice","volume":"32","author":"Twaddell","year":"2009","journal-title":"Aust Prescr"},{"key":"10.1016\/j.jhep.2022.12.017_bib8","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/0962280207082719","volume":"17","author":"Lassere","year":"2008","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.jhep.2022.12.017_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2019.104553","article-title":"Non-invasive biomarkers for chronic hepatitis B virus infection management","volume":"169","author":"Charre","year":"2019","journal-title":"Antivir Res"},{"key":"10.1016\/j.jhep.2022.12.017_bib10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1055\/s-0039-3401031","article-title":"Role of biomarkers in guiding cure of viral hepatitis B","volume":"40","author":"Buti","year":"2020","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2022.12.017_bib11","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/hep.31026","article-title":"Pregenomic HBV RNA and Hepatitis B Core-Related Antigen Predict Outcomes in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients Suppressed on Nucleos(T)ide Analogue Therapy","volume":"72","author":"Carey","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.12.017_bib12","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jhep.2018.11.030","article-title":"Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients","volume":"70","author":"Testoni","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.12.017_bib13","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2022.12.017_bib14","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cca.2013.02.006","article-title":"Brief critical review: statistical assessment of biomarker performance","volume":"419","author":"Kampfrath","year":"2013","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.jhep.2022.12.017_bib15","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1097\/JTO.0b013e3181ec173d","article-title":"Receiver operating characteristic curve in diagnostic test assessment","volume":"5","author":"Mandrekar","year":"2010","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jhep.2022.12.017_bib16","first-page":"69","article-title":"Statistics corner: a guide to appropriate use of correlation coefficient in medical research","volume":"24","author":"Mukaka","year":"2012","journal-title":"Malawi Med J"},{"key":"10.1016\/j.jhep.2022.12.017_bib17","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1213\/ANE.0000000000002864","article-title":"Correlation coefficients: appropriate use and interpretation","volume":"126","author":"Schober","year":"2018","journal-title":"Anesth Analg"},{"key":"10.1016\/j.jhep.2022.12.017_bib18","doi-asserted-by":"crossref","first-page":"23416","DOI":"10.1016\/S0021-9258(18)54512-9","article-title":"The hepatitis B virus S promoter comprises A CCAAT motif and two initiation regions","volume":"266","author":"Zhou","year":"1991","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jhep.2022.12.017_bib19","article-title":"Stronger enhancer II\/core promoter activities of hepatitis B virus isolates of B2 subgenotype than those of C2 subgenotype","volume":"6","author":"Qin","year":"2016","journal-title":"Sci Rep"},{"issue":"Suppl 1","key":"10.1016\/j.jhep.2022.12.017_bib20","doi-asserted-by":"crossref","first-page":"i6","DOI":"10.1136\/gutjnl-2012-302056","article-title":"New insight in the pathobiology of hepatitis B virus infection","volume":"61","author":"Dandri","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2022.12.017_bib21","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01695-20","article-title":"Characterization of hepatitis B precore\/core-related antigens","volume":"95","author":"Hong","year":"2021","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jhep.2022.12.017_bib22","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3350\/cmh.2020.0032","article-title":"Novel biomarkers for the management of chronic hepatitis B","volume":"26","author":"Inoue","year":"2020","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2022.12.017_bib23","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3350\/cmh.2021.0012","article-title":"Three heads are better than two: HBcrAg as a new predictor of HBV-related HCC","volume":"27","author":"Wu","year":"2021","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jhep.2022.12.017_bib24","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1146\/annurev.bi.56.070187.003251","article-title":"The molecular biology of the hepatitis B viruses","volume":"56","author":"Ganem","year":"1987","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.jhep.2022.12.017_bib25","doi-asserted-by":"crossref","first-page":"21713","DOI":"10.1074\/jbc.M501564200","article-title":"Hepatitis B virus DNA-negative dane particles lack core protein but contain a 22-kDa precore protein without C-terminal arginine-rich domain","volume":"280","author":"Kimura","year":"2005","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jhep.2022.12.017_bib26","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1128\/JCM.40.2.439-445.2002","article-title":"Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load","volume":"40","author":"Kimura","year":"2002","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.jhep.2022.12.017_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcv.2019.03.003","article-title":"Diagnostic and analytical performance of the hepatitis B core related antigen immunoassay in hepatitis B patients","volume":"114","author":"van Halewijn","year":"2019","journal-title":"J\u00a0Clin Virol"},{"key":"10.1016\/j.jhep.2022.12.017_bib28","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1111\/jgh.15058","article-title":"Use of hepatitis B virus core-related antigen to evaluate natural history of chronic hepatitis B","volume":"35","author":"Chan","year":"2020","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.12.017_bib29","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1002\/hep.31616","article-title":"HBV RNA profiles in patients with chronic hepatitis B under different disease phases and antiviral therapy","volume":"73","author":"Mak","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.12.017_bib30","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jhep.2021.02.017","article-title":"Clinical efficacy of a novel, high-sensitivity HBcrAg assay in the management of chronic hepatitis B and HBV reactivation","volume":"75","author":"Inoue","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.12.017_bib31","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/1469-0691.12739","article-title":"Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B","volume":"20","author":"Seto","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jhep.2022.12.017_bib32","doi-asserted-by":"crossref","first-page":"606 e601","DOI":"10.1016\/j.cmi.2015.02.010","article-title":"Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D","volume":"21","author":"Maasoumy","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jhep.2022.12.017_bib33","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12876-017-0703-9","article-title":"Distinct patterns of serum hepatitis B core-related antigen during the natural history of chronic hepatitis B","volume":"17","author":"Zhang","year":"2017","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jhep.2022.12.017_bib34","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3343\/alm.2019.39.1.67","article-title":"Performance of hepatitis B core-related antigen Vs. Hepatitis B surface antigen and hepatitis B virus DNA in predicting HBeAg-positive and HBeAg-negative chronic hepatitis","volume":"39","author":"Zhang","year":"2019","journal-title":"Ann Lab Med"},{"key":"10.1016\/j.jhep.2022.12.017_bib35","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.7754\/Clin.Lab.2017.161034","article-title":"Predictive value of hepatitis B core-related antigen (HBcrAg) during the natural history of hepatitis B virus infection","volume":"63","author":"Gou","year":"2017","journal-title":"Clin Lab"},{"key":"10.1016\/j.jhep.2022.12.017_bib36","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.cmi.2017.03.003","article-title":"Serum hepatitis B core-related antigen is more accurate than hepatitis B surface antigen to identify inactive carriers, regardless of hepatitis B virus genotype","volume":"23","author":"Riveiro-Barciela","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jhep.2022.12.017_bib37","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/apt.16258","article-title":"Incremental value of HBcrAg to classify 1582 HBeAg-negative individuals in chronic infection without liver disease or hepatitis","volume":"53","author":"Brunetto","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2022.12.017_bib38","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/jvh.13054","article-title":"Serum hepatitis B core-related antigen is an effective tool to categorize patients with HBeAg-negative chronic hepatitis B","volume":"26","author":"Loggi","year":"2019","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2022.12.017_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.jviromet.2021.114226","article-title":"Quantitative serum HBV markers in predicting phases of natural history of chronic HBV infection","volume":"296","author":"Zhang","year":"2021","journal-title":"J\u00a0Virol Methods"},{"key":"10.1016\/j.jhep.2022.12.017_bib40","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/jmv.24657","article-title":"Serum HBV core-related antigen is a good predictor for spontaneous HBeAg seroconversion in chronic hepatitis B patients","volume":"89","author":"Song","year":"2017","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.jhep.2022.12.017_bib41","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.4103\/0366-6999.189904","article-title":"HBcrAg identifies patients failing to achieve HBeAg seroconversion treated with pegylated interferon alfa-2b","volume":"129","author":"Ma","year":"2016","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.jhep.2022.12.017_bib42","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1080\/23744235.2018.1442018","article-title":"Comparison of hepatitis B virus core-related antigen and hepatitis B surface antigen for predicting HBeAg seroconversion in chronic hepatitis B patients with pegylated interferon therapy","volume":"50","author":"Wang","year":"2018","journal-title":"Infect Dis (Lond)"},{"key":"10.1016\/j.jhep.2022.12.017_bib43","doi-asserted-by":"crossref","first-page":"6927","DOI":"10.3748\/wjg.v27.i40.6927","article-title":"Serum hepatitis B core-related antigen as a surrogate marker of hepatitis B e antigen seroconversion in chronic hepatitis B","volume":"27","author":"Chi","year":"2021","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.12.017_bib44","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/jvh.12889","article-title":"HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues","volume":"25","author":"Wang","year":"2018","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2022.12.017_bib45","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1097\/CM9.0000000000001418","article-title":"Hepatitis B core-related antigen reflects viral replication and protein production in chronic hepatitis B patients","volume":"134","author":"Li","year":"2021","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.jhep.2022.12.017_bib46","doi-asserted-by":"crossref","first-page":"306 e307","DOI":"10.1016\/j.cmi.2017.07.016","article-title":"Predictive role of serum HBsAg and HBcrAg kinetics in patients with HBeAg-negative chronic hepatitis B receiving pegylated interferon-based therapy","volume":"24","author":"Chuaypen","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jhep.2022.12.017_bib47","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/jvh.12565","article-title":"Baseline HBsAg and HBcrAg titres allow peginterferon-based 'precision medicine' in HBeAg-negative chronic hepatitis B patients","volume":"23","author":"Martinot-Peignoux","year":"2016","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2022.12.017_bib48","doi-asserted-by":"crossref","first-page":"E172","DOI":"10.1111\/hepr.12287","article-title":"Serum levels of interleukin-22 and hepatitis B core-related antigen are associated with treatment response to entecavir therapy in chronic hepatitis B","volume":"44","author":"Okuhara","year":"2014","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2022.12.017_bib49","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/liv.13046","article-title":"Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B","volume":"36","author":"Chuaypen","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2022.12.017_bib50","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1872-034X.2007.00094.x","article-title":"Low serum level of hepatitis B core-related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy","volume":"37","author":"Matsumoto","year":"2007","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2022.12.017_bib51","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/jvh.13117","article-title":"Hepatitis B core-related antigen monitoring during peginterferon alfa treatment for HBeAg-negative chronic hepatitis B","volume":"26","author":"van Campenhout","year":"2019","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2022.12.017_bib52","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00535-017-1360-z","article-title":"Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue\/peg-interferon sequential therapy","volume":"53","author":"Matsumoto","year":"2018","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.jhep.2022.12.017_bib53","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s12072-021-10159-w","article-title":"Combining end-of-treatment HBsAg and baseline hepatitis B core-related antigen reduce HBV relapse rate after tenofovir cessation","volume":"15","author":"Kuo","year":"2021","journal-title":"Hepatol Int"},{"issue":"2","key":"10.1016\/j.jhep.2022.12.017_bib54","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.1016\/j.cgh.2021.04.031","article-title":"Switching to or add-on peginterferon in patients on nucleos(t)ide analogues for chronic hepatitis B: the SWAP RCT","volume":"20","author":"Lim","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.12.017_bib55","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/apt.16149","article-title":"Comparative biomarkers for HBsAg loss with antiviral therapy shows dominant influence of quantitative HBsAg (qHBsAg)","volume":"53","author":"Lim","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2022.12.017_bib56","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/jvh.13528","article-title":"The role of hepatitis B virus core-related antigen in predicting hepatitis B virus relapse after cessation of entecavir in hepatitis B e antigen-negative patients","volume":"28","author":"Huang","year":"2021","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2022.12.017_bib57","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.cca.2019.10.049","article-title":"HBcrAg, pg RNA and HBsAg dynamically supervise the seroconversion of HBsAg with anti-viral therapy: \"Loss of HBsAg\" maybe not a good end-point of anti-viral therapy","volume":"501","author":"Ma","year":"2020","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.jhep.2022.12.017_bib58","doi-asserted-by":"crossref","first-page":"4967","DOI":"10.2147\/IJGM.S321253","article-title":"Hepatitis B core-related antigen is a biomarker for off-treatment relapse after long-term nucleos(t)ide analog therapy in patients with chronic hepatitis B","volume":"14","author":"Liao","year":"2021","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.jhep.2022.12.017_bib59","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1007\/s12072-021-10186-7","article-title":"Combined viral quasispecies diversity and hepatitis B core-related antigen predict off-nucleos(t)ide analog durability in HBeAg-negative patients","volume":"15","author":"Cheng","year":"2021","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2022.12.017_bib60","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1111\/liv.14606","article-title":"Hepatitis B surface antigen, core-related antigen and HBV RNA: predicting clinical relapse after NA therapy discontinuation","volume":"40","author":"Kaewdech","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2022.12.017_bib61","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1872-034X.2011.00910.x","article-title":"Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B","volume":"42","author":"Matsumoto","year":"2012","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2022.12.017_bib62","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/infdis\/jiaa136","article-title":"Combining Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen: guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen-Positive Patients With Chronic Hepatitis B","volume":"222","author":"Fan","year":"2020","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jhep.2022.12.017_bib63","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1007\/s00535-021-01812-0","article-title":"HBeAg-positive patients with HBsAg < 100 IU\/mL and negative HBV RNA have lower risk of virological relapse after nucleos(t)ide analogues cessation","volume":"56","author":"Xie","year":"2021","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.jhep.2022.12.017_bib64","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1093\/infdis\/jiab596","article-title":"Earlier and Higher Rate of Hepatitis B Virus Relapse After Discontinuing Tenofovir Vs. Entecavir in Hepatitis B e Antigen-Positive Patients","volume":"225","author":"Chen","year":"2022","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jhep.2022.12.017_bib65","doi-asserted-by":"crossref","first-page":"e784","DOI":"10.1016\/j.cgh.2020.12.005","article-title":"Prediction of sustained response after nucleo(s)tide analogue cessation using HBsAg and HBcrAg levels: a multicenter study (CREATE)","volume":"20","author":"Sonneveld","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.12.017_bib66","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3851\/IMP3367","article-title":"Hepatitis B core-related antigen levels predict pegylated interferon-alpha therapy response in HBeAg-positive chronic hepatitis B","volume":"25","author":"Beudeker","year":"2020","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2022.12.017_bib67","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jviromet.2016.05.016","article-title":"Measurement of the hepatitis B core-related antigen is valuable for predicting the pathological status of liver tissues in chronic hepatitis B patients","volume":"235","author":"Zhang","year":"2016","journal-title":"J\u00a0Virol Methods"},{"key":"10.1016\/j.jhep.2022.12.017_bib68","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.cca.2018.07.027","article-title":"Clinical evaluation of hepatitis B core-related antigen in chronic hepatitis B and hepatocellular carcinoma patients","volume":"486","author":"Chen","year":"2018","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.jhep.2022.12.017_bib69","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1002\/hep.32018","article-title":"Comparison of HBV RNA and hepatitis B core related antigen with conventional HBV markers among untreated adults with chronic hepatitis B in north America","volume":"74","author":"Ghany","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.12.017_bib70","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/jvh.13211","article-title":"Predictors of hepatitis B surface antigen loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in noncirrhotic HBeAg-negative chronic hepatitis B","volume":"27","author":"Papatheodoridi","year":"2020","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2022.12.017_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2020.198117","article-title":"Evaluation of HBV serological markers in treatment-naive HBV mono-infected patients and HBV-HIV co-infected patients","volume":"290","author":"Jiang","year":"2020","journal-title":"Virus Res"},{"key":"10.1016\/j.jhep.2022.12.017_bib72","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/jvh.13097","article-title":"Relationship between hepatitis B core-related antigen levels and sustained HBeAg seroconversion in patients treated with nucleo(s)tide analogues","volume":"26","author":"Sonneveld","year":"2019","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2022.12.017_bib73","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01303-18","article-title":"Correlation of HBcrAg with intrahepatic hepatitis B virus total DNA and covalently closed circular DNA in HBeAg-positive chronic hepatitis B patients","volume":"57","author":"Wang","year":"2019","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.jhep.2022.12.017_bib74","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1111\/j.1440-1746.2005.04087.x","article-title":"Hepatitis B virus core and core-related antigen quantitation in Chinese patients with chronic genotype B and C hepatitis B virus infection","volume":"20","author":"Rokuhara","year":"2005","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.12.017_bib75","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1053\/j.gastro.2019.08.028","article-title":"High level of hepatitis B core-related antigen associated with increased risk of hepatocellular carcinoma in patients with chronic HBV infection of intermediate viral load","volume":"157","author":"Tseng","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.12.017_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2021.100540","article-title":"Hepatitis B core related antigen in relation to intrahepatic and circulating viral markers, before and after combination therapy","author":"Erken","year":"2021","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jhep.2022.12.017_bib77","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/hepr.12811","article-title":"Hepatitis B core-related antigen kinetics in chronic hepatitis B virus genotype D-infected patients treated with nucleos(t)ide analogues or pegylated-interferon-alpha","volume":"47","author":"Caviglia","year":"2017","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2022.12.017_bib78","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41598-017-00111-0","article-title":"Serum hepatitis B core-related antigen is a satisfactory surrogate marker of intrahepatic covalently closed circular DNA in chronic hepatitis B","volume":"7","author":"Chen","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2022.12.017_bib79","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1128\/JCM.00366-07","article-title":"Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection","volume":"45","author":"Wong","year":"2007","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.jhep.2022.12.017_bib80","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/jmv.21339","article-title":"Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients","volume":"81","author":"Suzuki","year":"2009","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.jhep.2022.12.017_bib81","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/liv.13346","article-title":"Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA","volume":"37","author":"Wong","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2022.12.017_bib82","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/jvh.13061","article-title":"Serum HBcrAg is better than HBV RNA and HBsAg in reflecting intrahepatic covalently closed circular DNA","volume":"26","author":"Chen","year":"2019","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2022.12.017_bib83","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3851\/IMP3280","article-title":"Monitoring of serum HBV RNA, HBcrAg, HBsAg and anti-HBc levels in patients during long-term nucleoside\/nucleotide analogue therapy","volume":"24","author":"Liao","year":"2019","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2022.12.017_bib84","doi-asserted-by":"crossref","first-page":"571 e575","DOI":"10.1016\/j.cmi.2016.02.002","article-title":"Hepatitis B core-related antigen levels are associated with response to\u00a0entecavir and peginterferon add-on therapy in hepatitis B e antigen-positive chronic hepatitis B patients","volume":"22","author":"van Campenhout","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jhep.2022.12.017_bib85","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/hepr.13574","article-title":"Deep sequencing analysis of serum hepatitis B virus-RNA during nucleot(s)ide analogue therapy","volume":"51","author":"Matsuda","year":"2021","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2022.12.017_bib86","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/cid\/ciaa013","article-title":"Hepatitis B virus RNA as early predictor for response to pegylated interferon alpha in HBeAg-negative chronic hepatitis B","volume":"72","author":"Farag","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2022.12.017_bib87","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1111\/j.1478-3231.2010.02344.x","article-title":"HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy","volume":"30","author":"Hosaka","year":"2010","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2022.12.017_bib88","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12985-020-01471-2","article-title":"Serum HBV RNA correlated with intrahepatic cccDNA more strongly than other HBV markers during peg-interferon treatment","volume":"18","author":"Wang","year":"2021","journal-title":"Virol J"},{"key":"10.1016\/j.jhep.2022.12.017_bib89","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/jgh.12182","article-title":"Significance of hepatitis B virus core-related antigen and covalently closed circular DNA levels as markers of hepatitis B virus re-infection after liver transplantation","volume":"28","author":"Matsuzaki","year":"2013","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.12.017_bib90","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/apt.14376","article-title":"Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection","volume":"47","author":"Mak","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2022.12.017_bib91","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms9102083","article-title":"Hepatitis B core-related antigen and new therapies for hepatitis B","volume":"9","author":"Watanabe","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.jhep.2022.12.017_bib92","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1055\/s-0041-1723088","article-title":"Hepatitis B core-related antigen: from virology to clinical application","volume":"41","author":"Lee","year":"2021","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2022.12.017_bib93","doi-asserted-by":"crossref","first-page":"e2353","DOI":"10.1002\/rmv.2353","article-title":"Hepatitis B virus core-related antigen (HBcrAg) as a prognostic marker for the development of hepatocellular carcinoma: a mini systematic review of the literature","author":"Afifi","year":"2022","journal-title":"Rev Med Virol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827822034699?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827822034699?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:48:05Z","timestamp":1759175285000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827822034699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":93,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0168827822034699"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2022.12.017","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A critique and systematic review of the clinical utility of hepatitis B core-related antigen","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2022.12.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}